Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
Cefepime/enmetazobactam demonstrated robust tissue distribution, reaching the applied pharmacokinetic/pharmacodynamic targets in all investigated tissue compartments, regardless of the mode of administration. From a pharmacokinetic view, cefepime/enmetazobactam may prove useful in future Gram-negative periprosthetic joint infection settings.
Authors
- Mats Bue (ORCID: https://orcid.org/0000-0001-7215-8323)
- Christoph Crocoll (ORCID: https://orcid.org/0000-0003-2754-3518)
- Alex Agustín Gutiérrez Soriano
- Josefine Slater (ORCID: https://orcid.org/0000-0002-3589-2278)
- Maiken Stilling (ORCID: https://orcid.org/0000-0002-4530-2075)
- Michal Poborsky (ORCID: https://orcid.org/0000-0002-7105-3316)
- M B D Nielsen
- C H Lützhøft
- N P Jørgensen
- H C Rasmussen
- M K D Mikkelsen
- M A Hvistendahl
Institutions
- University of Copenhagen (DK)
- Aarhus University (DK)
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- Hospital Clínic de Barcelona (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1093/jac/dkaf487
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00